Cargando…
Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial
BACKGROUND: Recent consensus guidelines recommend pregabalin as a first-tier treatment for painful diabetic peripheral neuropathy (DPN). We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using obj...
Autores principales: | Arezzo, Joseph C, Rosenstock, Julio, LaMoreaux, Linda, Pauer, Lynne |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2565674/ https://www.ncbi.nlm.nih.gov/pubmed/18796160 http://dx.doi.org/10.1186/1471-2377-8-33 |
Ejemplares similares
-
Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study
por: Arnold, Lesley M., et al.
Publicado: (2016) -
Pregabalin for the Prevention of Oxaliplatin‐Induced Painful Neuropathy: A Randomized, Double‐Blind Trial
por: de Andrade, Daniel Ciampi, et al.
Publicado: (2017) -
Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy: A randomized, double-blind trial
por: Razazian, Nazanin, et al.
Publicado: (2014) -
Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial
por: Markman, John, et al.
Publicado: (2018) -
Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
por: Carey, Dianne
Publicado: (2014)